Our assignment was to build a global pharmaceutical company brand from the ground up. Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader that develops, manufactures and commercializes therapies focused on hematology, oncology and immunology. Launched in 2015 following a separation from Baxter International, Baxalta has advanced biological manufacturing operations across 13 international facilities and its therapies are available in more than 100 countries. Baxalta employs more than 16,000 employees worldwide.

Working closely with Baxalta senior management, we utilized our proprietary Brand Vision™ process to develop the new Baxalta logo, a bold supporting brand, a global brand rollout approach and an ongoing integrated brand communications program. We continue to help Baxalta identify, streamline and implement brand communication materials across marketing channels.

In the words of Molly Painter, Baxalta’s Director U.S. Marketing, “Every once in a while you find a special group of people that just come together and do amazing things. This is that group. I know it sounds cliché, but they just get it. Our business is complex. It’s high-profile, proprietary and very time sensitive. Top down, Pivot over delivered on the ask at every turn.” We believe the results speak for themselves.